- Do you own shares of Tobira Pharmaceuticals, Inc. (NASDAQ CM: TBRA)?
- Did you purchase any of your shares prior to September 20, 2016?
- Do you think the proposed buyout price is too low?
Please contact Rigrodsky & Long, P.A. (“R & L”) to schedule a free consultation. You may call us or fill out our contact form so that we can call at your convenience. Your consultation will not create any obligation to use our services at any time.
R & L is investigating potential claims against the board of directors of Tobira Pharmaceuticals, Inc. concerning possible breaches of fiduciary duty and other violations of law related to the Company’s agreement to be acquired by Allergan plc for approximately $1.695 billion.